Idera Pharmaceuticals (IDRA)
Idera Pharmaceuticals Price / Book Value: 4.961
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
IDRA Price / Book Value Rankings
| Overall | 10th percentile | 3810 of 4242 |
| Sector | 24th percentile | 356 of 473 in Healthcare |
| Industry | 35th percentile | 93 of 144 in Biotechnology |
IDRA Price / Book Value Range, Past 5 Years
| Minimum | 1.958 | Sep 2011 |
| Maximum | 36.42 | Dec 2007 |
| Average | 8.414 |
About Price to Book Ratio
The price to book value is a financial ratio used to compare a company's book value to its current market price. Book value is an accounting term denoting the portion of the company held by the shareholders at accounting value (not market value). In other words, book value is the company's total tangible assets less its total liabilities.
The ratio has two calculation methods. In the first way, the company's market capitalization is divided by the company's total book value from its balance sheet. The second way, using per-share values, is to divide the company's current share price by the book value per share. In general, a low price to book value indicates that a stock is undervalued and thus more desirable.
In theory, if you purchased stock with a price to book value less than 1 and the company immediately went bankrupt, you would gain money on your investment. In reality, this may not be true since there are times when liquidation value, or the price at which a company's assets can be sold, is less than the book value of those assets.
Learn More
You may also be interested in these IDRA related companies
IDRA News
Idera Pharmaceuticals, Inc. (IDRA) Posts Narrower than Expected Q1 Loss
May 09, 7:49AM Street Insider
May 09, 7:49AM Street Insider
Idera Pharmaceuticals Announces Efficacy Data for IMO-8400 in Preclinical Models of Lupus and Psoriasis
May 07, 7:00AM Business Wire
May 07, 7:00AM Business Wire
Idera Pharmaceuticals Announces Presentation of Preclinical Data of IMO-8400 in Both Lupus and Psoriasis Models
May 01, 8:00AM Business Wire
May 01, 8:00AM Business Wire
Idera Pharmaceuticals to Present at the 11th Annual Needham Healthcare Conference
Mar 29, 8:30AM Business Wire
Mar 29, 8:30AM Business Wire
$IDRA http://stks.co/36xd tiny #BIOTECH with a nice round bottom on LT chart - $IDRA
about 63 days ago by LTbioinvestor
about 63 days ago by LTbioinvestor
Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results and Provides Pipeline Update
Mar 14, 8:30AM Business Wire
Mar 14, 8:30AM Business Wire
Idera Pharmaceuticals to Present at Cowen’s 32nd Annual Healthcare Conference
Feb 28, 9:05AM Business Wire
Feb 28, 9:05AM Business Wire
Idera Pharmaceuticals to Present at Cancer Immunotherapy Summit on February 28th
Feb 27, 9:05AM Business Wire
Feb 27, 9:05AM Business Wire
Idera Pharmaceuticals Announces Retirement of Dr. James B. Wyngaarden as a Member of the Board of Directors
Feb 17, 9:05AM Business Wire
Feb 17, 9:05AM Business Wire
$IDRA making a move before BioCEO presentation tomorrow morning. Glad I picked some up cheap last week.
about 106 days ago by illinijill
about 106 days ago by illinijill
$IDRA http://stks.co/2MeF tiny BIO name, chart looks ready for a move, on watch for a possible speculative buy - $IDRA
about 107 days ago by LTbioinvestor
about 107 days ago by LTbioinvestor
CORRECTING and REPLACING Idera Pharmaceuticals to Present at BIO CEO Conference February 13th, 2012
Feb 06, 10:23AM Business Wire
Feb 06, 10:23AM Business Wire
Idera Pharmaceuticals presents positive data on IMO-4200 preclinical models
Dec 13, 4:20PM theflyonthewall.com
Dec 13, 4:20PM theflyonthewall.com
Idera Pharmaceuticals files to sell 8.43M of common stock for holders
Dec 09, 4:16PM theflyonthewall.com
Dec 09, 4:16PM theflyonthewall.com
Idera Pharmaceuticals (IDRA) Receives FDA Approval to Proceed with Phase 2 Trials of IMO-3100
Dec 01, 8:40AM Street Insider
Dec 01, 8:40AM Street Insider
Idera Pharmaceuticals announces FDA authorization for Phase 2 IMO-3100 trial
Dec 01, 8:37AM FlyOnTheWall
Dec 01, 8:37AM FlyOnTheWall
Idera Pharmaceuticals Regains Global Rights to IMO-2055 in Oncology from Merck KGaA
Nov 30, 8:33AM Benzinga
Nov 30, 8:33AM Benzinga
Idera Pharma (IDRA) Reports Encouraging Preclinical Data for Novel GSO Technology
Nov 15, 8:45AM Street Insider
Nov 15, 8:45AM Street Insider
$IDRA great pharma name w/ tremendous potential. Hidden Gem if there ever was 1. Could be a 10-bagger next year same time. Very strong buy
about 260 days ago by pumpndumphunter
about 260 days ago by pumpndumphunter
$IDRA
Idera Reports Clinical Hold on Proposed Phase 2 Clinical Trial of IMO-3100
about 314 days ago by Benzinga
about 314 days ago by Benzinga
Idera Pharma $IDRA reports clinical hold on proposed Phase 2 trial of IMO-3100
about 314 days ago by Street_Insider
about 314 days ago by Street_Insider
Idera $IDRA says Merck won't conduct further development on IMO-2055, will complete ongoing Phase 2 with Erbitux; stock halted
about 328 days ago by Street_Insider
about 328 days ago by Street_Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| IDRA | 1.00 | -0.02 | -1.96% | 27.64M |
| IDN | 1.64 | -0.09 | -5.07% | 47.44M |
| IDIX | 9.41 | -0.27 | -2.79% | 1.041B |
| IDI | 1.85 | -0.03 | -1.60% | 38.59M |
| IDCC | 25.28 | +0.14 | +0.56% | 1.134B |
| IDA | 39.30 | +0.17 | +0.43% | 1.955B |
| ICUI | 52.22 | +0.21 | +0.40% | 722.94M |
| ICS | 15.36 | +0.07 | +0.46% | |
| ICON | 15.86 | +0.38 | +2.45% | 1.123B |
| ICLR | 21.90 | -0.03 | -0.14% | 1.319B |
